Catherine A. Hulford

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

W. Gregory Roberts, Ethan Ung, Pamela Whalen et al. · Cancer Research · 2008 · 381 citations · Full text

Medicine, Oncology, Pharmacology +17

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis

Leonard Buckbinder, David T. Crawford, Hong Qi et al. · Proceedings of the National Academy of Sciences · 2007 · 157 citations · Full text

Medicine, Biochemistry, Molecular Biology +17

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

Daniel P. Walker, F. Christopher Bi, Amit S. Kalgutkar et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin

David J. Bernhardson, Thomas A. Brandt, Catherine A. Hulford et al. · Organic Process Research & Development · 2014 · 44 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Identification of (<i>R</i>)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1<i>H</i>-pyrazol-3-yl)-2-methoxynicotinic Acid, a Highly Potent and Selective Nonsteroidal Mineralocorticoid Receptor Antagonist

Agustin Casimiro‐Garcia, David W. Piotrowski, Catherine M. Ambler et al. · Journal of Medicinal Chemistry · 2014 · 28 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16